About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3693373
Allelic
Composition
Tg(tetO-BCR/ABL1)2Dgt/0
Tg(Tal1-tTA)19Dgt/0
Genetic
Background
involves: C57BL/6 * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Tal1-tTA)19Dgt mutation (2 available)
Tg(tetO-BCR/ABL1)2Dgt mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging

hematopoietic system
• after induction by withdrawal of tet treatment, splenomegaly invariably results
• readministration of tet results in disappearance of palpable splenomegaly
• 12 days after BCR/ABL induction, bone marrow shows a 7-fold increase in hematopoietic stem cells and a 26-fold increase after 21 days; at both points, granulocyte-macrophage progenitor (GMP) percentage is increased 3-fold, while megakaryocyte-erythroid progenitors (MEP) show a 3-fold decrease
• common myeloid precursors (CMP) show a 2-fold decrease and a 1.5-fold increase at 12 and 21 days, respectively
• some mice (31%) show progression to lymphoid blast crisis with lymph node enlargement and lymphoblasts in peripheral blood; lymphooblasts are found to be arrested at different maturation stages
• bone marrow of diseased mice is hypercellular
• increased numbers of cells of lymphoid and myeloid lineage are detected in diseased mice
• increased numbers of megakaryocytes are detected in bone marrow and spleen of diseased mice
• bone marrow contains increased ratio of myeloid and erythroid cells dominated by granulocytic forms
• increase in immature myeloid cells is observed
• absolute number is increased 2-fold in peripheral blood 2 weeks after tet withdrawal (BCR/ABL induction)
• readministration of tet results in reversion of leukocytosis in approximately ~4 days
• percentage and absolute number of neutrophils are increased 3- and 5- fold in peripheral blood 2 weeks after tetracycline (tet) withdrawal compared to wild-type or single transgenic mice
• readministration of tet results in reversion of neutrophilia in approximately ~4 days
• 12 days after BCR/ABL induction, bone marrow shows a 7-fold increase in hematopoietic stem cells
• after induction of BCR/ABL expression, expansion of spleen red pulp by granulocytic myeloid cells is observed at various time points
• induction of BCR/ABL increases numbers of erythroid and granulocytic-monocytic progenitor cells in spleen

immune system
• after induction by withdrawal of tet treatment, splenomegaly invariably results
• readministration of tet results in disappearance of palpable splenomegaly
• some mice (31%) show progression to lymphoid blast crisis with lymph node enlargement and lymphoblasts in peripheral blood; lymphooblasts are found to be arrested at different maturation stages
• absolute number is increased 2-fold in peripheral blood 2 weeks after tet withdrawal (BCR/ABL induction)
• readministration of tet results in reversion of leukocytosis in approximately ~4 days
• percentage and absolute number of neutrophils are increased 3- and 5- fold in peripheral blood 2 weeks after tetracycline (tet) withdrawal compared to wild-type or single transgenic mice
• readministration of tet results in reversion of neutrophilia in approximately ~4 days
• after induction of BCR/ABL expression, expansion of spleen red pulp by granulocytic myeloid cells is observed at various time points
• induction of BCR/ABL increases numbers of erythroid and granulocytic-monocytic progenitor cells in spleen
• infiltration by myeloid cells is observed

liver/biliary system
• infiltration of liver by myeloid cells is observed after induction; 57% of mice display hepatomegaly

respiratory system
• infiltration by myeloid cells is observed, occasionally resulting in focal pulmonary hemorrhages

digestive/alimentary system
• infiltration of lamina propria by myeloid cells is observed

neoplasm
• some mice develop lymphomas
• readministration of tet results in disappearance of lymphomas (except in 1 case)
• 2 animals with fulminant disease displayed skin chloromas (granulocytic sarcomas)

growth/size/body
• infiltration of liver by myeloid cells is observed after induction; 57% of mice display hepatomegaly
• after induction by withdrawal of tet treatment, splenomegaly invariably results
• readministration of tet results in disappearance of palpable splenomegaly

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
chronic myeloid leukemia DOID:8552 OMIM:608232
J:96511


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory